GlassScriptPhysician profile
Jennifer Lang
NPI 1003364795
$5,642.17
in general payments reported to CMS, 2019-2025
29 companies · $1,928 in 2025
The $1,928 reported for 2025 was more than what 95% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $160 · 2022: $503 · 2023: $1,287 · 2024: $1,764 · 2025: $1,928.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,885 · Education: $94.14.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,885.01 |
| Education | $94.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,460.22 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $537.97 | 2022-2025 | Xifaxan, Trulance |
| Takeda Pharmaceuticals U.S.A., INC. | $486.02 | 2021-2025 | Entyvio |
| Janssen Biotech, INC. | $468.09 | 2022-2025 | Tremfya, Stelara |
| Pfizer INC. | $271.79 | 2024-2025 | |
| Genzyme Corporation | $271.51 | 2022-2025 | |
| Phathom Pharmaceuticals, INC. | $248.60 | 2023-2025 | Voquezna |
| Celgene Corporation | $230.10 | 2022-2023 | Zeposia |
| Ardelyx, INC. | $222.83 | 2022-2025 | Ibsrela |
| Lilly USA, LLC | $203.56 | 2023-2025 | Omvoh |
| Qol Medical, LLC | $189.17 | 2023-2024 | Sucraid, Sucraid |
| Celltrion USA INC. | $163.14 | 2023-2025 | Zymfentra, Vegzelma, Yuflyma |
| Janssen Scientific Affairs, LLC | $127.49 | 2025 | Tremfya |
| Intercept Pharmaceuticals, INC. | $101.23 | 2022-2025 | |
| Ipsen Biopharmaceuticals, INC | $91.10 | 2025 | Iqirvo |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Renovia INC | $86.81 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $67.24 | 2022-2024 | Dupixent |
| Ferring Pharmaceuticals INC. | $60.64 | 2023-2025 | Rebyota |
| Ironwood Pharmaceuticals, INC | $54.13 | 2024 | |
| Novo Nordisk INC | $46.32 | 2025 | Wegovy |
| Braintree Laboratories, INC. | $46.09 | 2023 | Sutab |
| Aimmune Therapeutics, INC. | $41.10 | 2024 | |
| Fresenius Kabi USA, LLC | $32.56 | 2024 | Idacio |
| Merck Sharp & Dohme LLC | $31.10 | 2023 | Zinplava, Dificid |
| Sandoz INC. | $24.44 | 2024 | Hyrimoz |
| Organon LLC | $24.34 | 2025 | Hadlima, Renflexis |
| Madrigal Pharmaceuticals | $20.91 | 2025 | Rezdiffra |
| Amgen INC. | $18.53 | 2023 | Avsola, Amjevita |
| Endogastric Solutions, INC | $15.14 | 2024 | Esophyx |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jennifer Lang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.